FibroBiologics

Houston, Texas, September 1, 2026 FibroBiologics, Inc. has announced the issuance of a new U.S. patent covering a potential...

Caesarea, Israel, August 20, 2026 IceCure Medical has announced an important clinical development for its minimally invasive ProSense® cryoablation...

Houston, Texas, August 20, 2026 FibroBiologics, Inc., a clinical-stage biotechnology company developing regenerative therapies based on fibroblast cells and...

HOUSTON, August 18, 2026 FibroBiologics, Inc., a clinical-stage biotechnology company developing therapies based on fibroblast cells and fibroblast-derived materials,...

NEEDHAM, Massachusetts, August 11, 2026 Mighty Therapeutics, a commercial-stage biotechnology company focused on therapies targeting mitochondrial dysfunction, and a...

HOUSTON, Texas, August 11, 2026 FibroBiologics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued...

HOUSTON, July 7, 2026 FibroBiologics, Inc. has announced the successful completion of the third manufacturing batch of its investigational...

HOUSTON, June 16, 2026 FibroBiologics announced that the first patients have been dosed in its ongoing Phase 1/2 clinical...

HOUSTON, May 22, 2026 FibroBiologics, Inc. announced new preclinical data from its CYPS317 psoriasis program demonstrating durable immune modulation...

Houston, Texas — February 10, 2026: FibroBiologics, Inc., a clinical-stage biotechnology company advancing fibroblast-based therapeutics, announced that its Chairman...